Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease
The DOI matches its Crossref record; 33 of the 36 references it cites were found in a registry or an index.
Abstract
PURPOSE: Siltuximab (IL6 antibody) is approved for the treatment of multicentric Castleman disease (MCD). Effects of IL6 inhibition on the inflammatory milieu accompanying MCD have not been characterized. EXPERIMENTAL DESIGN: Trends in inflammatory- and anemia-associated markers, measured over the course of a placebo-controlled study of siltuximab (11 mg/kg q3w) in patients with MCD (n = 79), were characterized. RESULTS: Baseline IL6 and C-reactive protein (CRP) levels were significantly correlated (r = 0.708; P < 0.0001). CRP levels decreased (median, 92%) by cycle 1 day 8 (C1D8), remaining suppressed during siltuximab treatment while remaining stable in the placebo group. There were no associations between baseline CRP or IL6 and MCD symptom burden, histologic subtype, ethnicity, maximum CRP decrease, and response parameters. A hemoglobin response (change ≥ 15 g/L at week 13) was observed with siltuximab (61%; P = 0.0002). Median hepcidin decrease from baseline at C1D8 with siltuximab was 47% versus median 11% increase with placebo. Maximum post-baseline changes in hepcidin levels among siltuximab recipients were correlated with maximum changes for hemoglobin (r = -0.395; P = 0.00607), total iron-binding capacity (TIBC; r = -0.354; P = 0.01694), and ferritin (r = 0.599; P = 0.0001). Greater median changes from baseline in ferritin, hemoglobin, and TIBC were observed in anemic siltuximab-treated patients. CONCLUSIONS: IL6 neutralization with siltuximab resulted in sustained CRP suppression and improvement of anemia, in part, by hepcidin pathway inhibition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Supporting evidence is provided by studies with multicentric Castleman disease patients who were treated with therapeutic monoclonal antibodies against IL-6 receptor (tocilizumab) or IL-6 (siltuximab). These treatments reduced hepcidin levels and improved anemia (Song et al., 2010; Casper et al., 2015).”
From Pharmacological Targeting of the Hepcidin/Ferroportin Axis (2016) · cites this paper as Casper et al., 2015
Citations
Cites
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18921 · Cited by 3,503
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318921 · Cited by 3,436
Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650 · cited 1×
“Neutralization of IL6 by siltuximab is hypothesized to decrease hepcidin releasing sequestered iron leading to improvement in hemoglobin levels (32).”
BackgroundKishimoto, T. (1989) · Blood · doi:10.1182/blood.v74.1.1.1 · Cited by 2,069
Localized mediastinal lymph-node hyperplasia resembling thymoma
Castleman, B., Iverson, L., & Menendez, V. P. (1956) · Cancer · doi:10.1002/1097-0142(195607/08)9:4<822::aid-cncr2820090430>3.0.co;2-4 · Cited by 1,621 · cited 1×
“Castleman disease was first described by Benjamin Castleman in 1956 as a solitarymediastinal tumor resembling thymoma and characterized by lymph node hyperplasia with germinal center formation and marked capillary proliferation (1).”
BackgroundNicolas, G., Chauvet, C., Viatte, L., Danan, J. L., Bigard, X., Devaux, I., Beaumont, C., Kahn, A., & Vaulont, S. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215686 · Cited by 1,214 · cited 1×
“Although IL6 is the primary inducer of hepcidin production by hepatocytes, IL6-independent pathways may also decrease hepcidin levels with or without concomitant increases in hemoglobin (33, 34).”
BackgroundPathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease
Yoshizaki, K., Matsuda, T., Nishimoto, N., Kuritani, T., Taeho, L., Aozasa, K., Nakahata, T., Kawai, H., Tagoh, H., & Komori, T. (1989) · Blood · doi:10.1182/blood.v74.4.1360.1360 · Cited by 928
BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism
Andriopoulos Jr, B., Corradini, E., Xia, Y., Faasse, S. A., Chen, S., Grgurevic, L., Knutson, M. D., Pietrangelo, A., Vukicevic, S., Lin, H. Y., et al. (2009) · Nature Genetics · doi:10.1038/ng.335 · Cited by 769 · cited 1×
“Although IL6 is the primary inducer of hepcidin production by hepatocytes, IL6-independent pathways may also decrease hepcidin levels with or without concomitant increases in hemoglobin (33, 34).”
BackgroundCastell, J. V., Gómez-lechón, M. J., David, M., Fabra, R., Trullenque, R., & Heinrich, P. C. (1990) · Hepatology · doi:10.1002/hep.1840120517 · Cited by 757 · cited 1×
“IL6 is the primary inducer of hepaticCRPproduction (18).”
Background
Cited by
Dispenzieri, A., & Fajgenbaum, D. C. (2020) · Blood · doi:10.1182/blood.2019000931 · Cited by 487
The ‘cytokine storm’: molecular mechanisms and therapeutic prospects
Karki, R., & Kanneganti, T.-D. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.06.001 · Cited by 438
van Rhee, F., Voorhees, P., Dispenzieri, A., Fosså, A., Srkalovic, G., Ide, M., Munshi, N., Schey, S., Streetly, M., Pierson, S. K., et al. (2018) · Blood · doi:10.1182/blood-2018-07-862334 · Cited by 426
Self-citationInterplay between interleukin-6 signaling and the vascular endothelium in cytokine storms
Kang, S., & Kishimoto, T. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00649-0 · Cited by 375
Idiopathic multicentric Castleman's disease: a systematic literature review
Liu, A. Y., Nabel, C. S., Finkelman, B. S., Ruth, J. R., Kurzrock, R., van Rhee, F., Krymskaya, V. P., Kelleher, D., Rubenstein, A. H., & Fajgenbaum, D. C. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)00006-5 · Cited by 330
Metadata
- Authors
- Casper, C., Chaturvedi, S., Munshi, N., Wong, R., Qi, M., Schaffer, M., Bandekar, R., Hall, B., van de Velde, H., Vermeulen, J., Reddy, M., & van Rhee, F.
- Affiliations
- Fred Hutch Cancer Center (US)
- 2Janssen Research & Development, Spring House, Pennsylvania.
- Harvard University (US)
- Chinese University of Hong Kong (HK)
- 5Janssen Research & Development, Beerse, Belgium.
- Janssen (Netherlands) (NL)
- 7Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas.
- Corresponding author
- Casper, Corey
- Venue
- Clinical Cancer Research
- Published
- 2015-09-30
- Volume
- 21
- Issue
- 19
- Pages
- 4294-4304
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2120581070
- Cited by
- 97
- References
- 36
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 12 · 2023: 4 · 2022: 7 · 2021: 12 · 2020: 8 · 2019: 7 · 2018: 14 · 2017: 12 · 2016: 4 · 2015: 5
- FWCI
- 5.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphadenopathy Diagnosis and Analysis
- Keywords
- siltuximab, multicentric Castleman disease, IL-6 inhibition, anemia, hepcidin, C-reactive protein, ferritin, total iron binding capacity, inflammatory markers, hemoglobin response
- MeSH terms
- Interleukin-6 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Agents, C-Reactive Protein, Erythrocyte Indices, Female, Castleman Disease, Humans, Iron, Male, Middle Aged, Biomarkers, Interleukin-6, Treatment Outcome, Young Adult, Hepcidins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-0134
- The paper
- Casper, C., Chaturvedi, S., Munshi, N., Wong, R., Qi, M., Schaffer, M., Bandekar, R., Hall, B., van de Velde, H., Vermeulen, J., Reddy, M., & van Rhee, F. (2015). Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-0134
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.